Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B CAMBRIDGE, Mass., Jan. 31, 2017 — Dimension Therapeutics, Inc. , a biopharmaceutical company advancing novel, adeno-associated virus gene therapies targeting the liver, a key organ for human metabolism, today announced preliminary topline safety and early efficacy results of Dimension’s multi-center phase 1/2 study of DTX101 for the treatment of adult patients with moderate/severe to severe hemophilia B. DTX101, Dimension’s lead AAV candidate, is designed to deliver stable expression of blood clotting Factor IX in patients with hemophilia B, a rare genetic bleeding disorder resulting from a deficiency in FIX.